MITRO

MITRO is a leading Chinese contract research and contract development/manufacturing organization specializing in radiolabeled molecular imaging and radiopharmaceuticals. It offers end-to-end services from in vitro discovery, radiochemistry, preclinical and clinical development, to regulatory submission. The company has completed its first GMP production of radiopharmaceuticals, gained clinical trial approvals, and expanded into the US and UK. MITRO merged with XingImaging in 2023, further enhancing its capabilities in neuroscience and oncology imaging. Its pipeline is primarily focused on oncology, neurology, and innovative therapies, with a notable Phase 1/2 trial for a PSMA-targeted radiopharmaceutical in prostate cancer, and involvement in clinical imaging trials for neuroimaging tracers and immune-oncology drugs.